Aktienanalyse zu Dexcom Inc (DXCM)DXCMDexcom Inc

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Dexcom Inc is a good buy right now, trading at $84.11 with a forward P/E ratio of 28.25, indicating growth potential. The stock has shown a year-to-date increase of 26.41%, reflecting strong demand for its products. Analysts have set a price target range of $90 to $115, suggesting significant upside potential. However, the current RSI of 35.38 indicates that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent 5-day change of -1.46%, indicating short-term volatility.

18 analysts cover DXCM: 11 rate it Buy, 7 Hold and 0 Sell. The average price target is 82.54.